First real-life experiences with 2 mg bulevirtide for the treatment of hepatitis delta-data from a tertiary reference centre in Germany

被引：0
|
作者：
Zoellner, Caroline [1 ,2 ]
Lutz, Katrin [1 ,2 ]
Demir, Muenevver [1 ,2 ]
Tacke, Frank [1 ,2 ]
机构：
[1] Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, Campus Virchow Klinikum, Berlin, Germany
[2] Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PO-1419
引用
收藏
页码：S745 / S746
页数：2
相关论文
共 50 条
  • [31] Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry
    Sara Monti
    Catherine Klersy
    Roberto Gorla
    Piercarlo Sarzi-Puttini
    Fabiola Atzeni
    Raffaele Pellerito
    Enrico Fusaro
    Giuseppe Paolazzi
    Pier Andrea Rocchetta
    Ennio Giulio Favalli
    Antonio Marchesoni
    Roberto Caporali
    Clinical Rheumatology, 2017, 36 : 753 - 761
  • [32] Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry
    Monti, Sara
    Klersy, Catherine
    Gorla, Roberto
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    Pellerito, Raffaele
    Fusaro, Enrico
    Paolazzi, Giuseppe
    Rocchetta, Pier Andrea
    Favalli, Ennio Giulio
    Marchesoni, Antonio
    Caporali, Roberto
    CLINICAL RHEUMATOLOGY, 2017, 36 (04) : 753 - 761
  • [33] The 12-Years Retention Rate of the First-Line TNF-Inhibitor in the Treatment of Rheumatoid Arthritis: Real-Life Data from a Local Registry
    Favalli, Ennio Giulio
    Biggioggero, Martina
    Pregnolato, Francesca
    Becciolini, Andrea
    Penatti, Alessandra Emiliana
    Marchesoni, Antonio
    Meroni, Pier Luigi
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1038 - S1038
  • [34] Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Viacheslav, Morozov
    Sagalova, Olga
    Stepanova, Tatyana
    Manuilov, Dmitry
    Suri, Vithika
    An, Qi
    Flaherty, John F.
    Osinusi, Anu
    Zur Wiesch, Julian Schulze
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2022, 77 : S4 - S5
  • [35] EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia R.
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana V.
    Manuilov, Dmitry
    Shah, Vicki
    Suri, Vithika
    An, Qi
    Flaherty, John F.
    Osinusi, Anu
    zur Wiesch, Julian Schulze
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    GASTROENTEROLOGY, 2023, 164 (06) : S1367 - S1368
  • [36] Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022-2023-Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre
    Liu, Justin K. H.
    Harrison, Stephanie R.
    Lee, Dan
    LUNG CANCER, 2024, 190
  • [37] Treatment of chronic hepatitis c with peginterferon alfa-2A (400) (PEG) and ribavirin (RBV) in naive patients with HIV-HCV co-infection in the real-life setting in germany
    Zehnter, Elmor
    Mauss, Stefan
    Boeker, Klaus
    Lutz, Thomas
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innesso
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Moeller, Bernd
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    HEPATOLOGY, 2007, 46 (04) : 362A - 362A
  • [38] Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers
    Sandmann, Lisa
    Doerge, Petra
    Wranke, Anika
    Vermehren, Johannes
    Welzel, Tania M.
    Berg, Christoph P.
    Grottenthaler, Julia M.
    Weiss, Karl-Heinz
    Langel, Jessica
    Sterneck, Martina
    von Wulffen, Moritz
    Manns, Michael P.
    Wedemeyer, Heiner
    Hardtke, Svenja
    von Hahn, Thomas
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (08) : 1049 - 1056
  • [39] Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register
    Antonucci, Emilia
    Migliaccio, Ludovica
    Abbattista, Maria
    Caronna, Antonella
    De Marchi, Sergio
    Di Giorgio, Angela
    Di Giulio, Rosella
    Lerede, Teresa
    Garzia, Maria Grazia
    Martinelli, Ida
    Mastroiacovo, Daniela
    Marzolo, Marco
    Montevecchi, Elisa
    Pastori, Daniele
    Pignatelli, Pasquale
    Poli, Daniela
    Ria, Luigi
    Santoliquido, Angelo
    Testa, Sophie
    Palareti, Gualtiero
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [40] ADJUVANT TREATMENT VERSUS INITIAL OBSERVATION IN NEWLY DIAGNOSED WHO GRADE II AND GRADE III OLIGODENDROGLIOMA: REAL-LIFE DATA FROM TWO ACADEMIC, TERTIARY CARE CENTERS IN AUSTRIA
    Mair, M. J.
    Leibetseder, A.
    Woehrer, A.
    Widhalm, G.
    Dieckmann, K.
    Aichholzer, M.
    Weis, S.
    von Oertzen, T.
    Pichler, J.
    Preusser, M.
    Berghoff, A. S.
    NEURO-ONCOLOGY, 2021, 23 : 40 - 41
12345